X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse VENUS REMEDIES with ACTAVIS INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs ACTAVIS (US) - Comparison Results

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 VENUS REMEDIES   ACTAVIS
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-16
ACTAVIS
Dec-14
VENUS REMEDIES/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs21817,748-   
Low Rs8210,826-   
Sales per share (Unadj.) Rs365.63,196.0-  
Earnings per share (Unadj.) Rs1.5-398.8-  
Cash flow per share (Unadj.) Rs37.9293.2-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs382.56,932.0-  
Shares outstanding (eoy) m11.44265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.44.5 9.2%   
Avg P/E ratio x101.0-35.8 -281.9%  
P/CF ratio (eoy) x4.048.7 8.1%  
Price / Book Value ratio x0.42.1 19.0%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,7173,798,960 0.0%   
No. of employees `0001.021.6 4.7%   
Total wages/salary Rs m3240-   
Avg. sales/employee Rs Th4,100.739,343.2 10.4%   
Avg. wages/employee Rs Th318.00-   
Avg. net profit/employee Rs Th16.7-4,909.6 -0.3%   
INCOME DATA
Net Sales Rs m4,183849,814 0.5%  
Other income Rs m20-2,121 -0.9%   
Total revenues Rs m4,203847,693 0.5%   
Gross profit Rs m812109,171 0.7%  
Depreciation Rs m417184,016 0.2%   
Interest Rs m38026,805 1.4%   
Profit before tax Rs m35-103,771 -0.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-7,612 0.0%   
Tax Rs m18-5,335 -0.3%   
Profit after tax Rs m17-106,048 -0.0%  
Gross profit margin %19.412.8 151.0%  
Effective tax rate %51.65.1 1,003.0%   
Net profit margin %0.4-12.5 -3.3%  
BALANCE SHEET DATA
Current assets Rs m2,771447,743 0.6%   
Current liabilities Rs m1,931326,536 0.6%   
Net working cap to sales %20.114.3 140.7%  
Current ratio x1.41.4 104.6%  
Inventory Days Days12558 215.5%  
Debtors Days Days5466 81.1%  
Net fixed assets Rs m5,328103,771 5.1%   
Share capital Rs m1140-   
"Free" reserves Rs m4,1770-   
Net worth Rs m4,3761,843,215 0.2%   
Long term debt Rs m1,911965,881 0.2%   
Total assets Rs m8,4283,378,006 0.2%  
Interest coverage x1.1-2.9 -38.0%   
Debt to equity ratio x0.40.5 83.3%  
Sales to assets ratio x0.50.3 197.3%   
Return on assets %4.7-2.3 -200.7%  
Return on equity %0.4-5.8 -6.8%  
Return on capital %6.6-3.0 -219.2%  
Exports to sales %00-   
Imports to sales %20.50-   
Net fx Rs m-8580-   
CASH FLOW
From Operations Rs m469145,930 0.3%  
From Investments Rs m29-349,411 -0.0%  
From Financial Activity Rs m-464196,319 -0.2%  
Net Cashflow Rs m35-7,163 -0.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 65.06 Rs / USD

Compare VENUS REMEDIES With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare VENUS REMEDIES With: SANOFI INDIA  DISHMAN PHARMA  ALEMBIC LTD  FULFORD INDIA  PIRAMAL ENTERPRISES  



Today's Market

Indian Indices Trade Marginally Lower; Energy Stocks Witness Losses(11:30 am)

Share markets in India are presently trading marginally lower. Sectoral indices are trading on a mixed note with stocks in the energy sector and auto sector witnessing maximum selling pressure.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Feb 22, 2018 01:05 PM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS